CasInvent Pharma Launches Crowdfunding Campaign in Cooperation with Capital Cell

CasInvent Pharma has officially launched a crowdfunding campaign in partnership with Capital Cell, Europe’s leading life-science investment platform. The campaign will support the advancement of our first-in-class CK1 inhibitor program as we prepare all the requirements for the entrance into clinical trials.

About the scientific opportunity

CasInvent is developing a new class of small-molecule inhibitors capable of targeting all three clinically relevant CK1 isoforms (CK1α, CK1δ, CK1ε). This broad inhibition strategy is designed to block cancer cell compensation mechanisms, offering a more robust therapeutic effect, particularly in blood cancers where resistance to for example Venetoclax is a major challenge.

Why we chose Capital Cell

Capital Cell specializes exclusively in biotechnology and healthcare projects, combining traditional venture financing practices with the accessibility of equity crowdfunding. The platform performs rigorous scientific and financial due diligence, giving investors a transparent and regulated environment to participate in early-stage biotech opportunities.

Opportunity for investors

To reach IND application (entering clinical trials), CasInvent is raising €500,000 through crowdfunding, with a minimum investment of €2,000. Early supporters have the opportunity to enter at a low valuation, creating the potential for significant upside. With an estimated ROI of ≈ 37.8×, a €2,000 investment could translate into a return of roughly €75,000 at exit, offering an attractive high-growth addition to a diversified portfolio.

CasInvent aims to achieve IND approval in 2026 and initiate a Phase 1 clinical trial in 2027, positioning the company for a planned exit in 2029.

For full details about the campaign and investment terms, please visit: https://capitalcell.com/en/campaign/casinvent/